Diwakar Davar, MBBS, MSc, discusses how data from the phase I trial of TSR-022, an anti-TIM-3 monoclonal antibody, and TSR-042, an anti-PD-1 agent, impact the treatment of patients with both melanoma and lung cancer.
Diwakar Davar, MBBS, MSc, assistant professor of medicine and medical oncologist/hematologist at UPMC Hillman Cancer Center, discusses how data from a phase I trial of TSR-022, an anti-TIM-3 monoclonal antibody, and TSR-042, an anti-PD-1 agent, impact the treatment of patients with both melanoma and lung cancer.
PD-1 checkpoint inhibition has been dominant in the treatment paradigm, says Davar, as it produces significant responses in both disease settings. According to these data, this combination is both safe and efficacious in patients who are refractory to PD-1.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More